CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 45 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05290623
NCT05290623N/ACompleted

High-power Green-light Laser Endoscopic Submucosal Dissection for Non-muscle-invasive Bladder Cancer: a Technical Improvement and Its Initial Application

Shandong Provincial Hospital·observational·Posted Mar 22, 2022·Updated Mar 22, 2022

In Brief

An observational study for Bladder Cancer. Completed, enrolled 45 participants across 1 site.

Detailed Summary

A retrospective study was designed in this study. The surgeon performed high-power green-light laser endoscopic submucosal dissection (HPL-ESD) for the treatment of primary non-muscle-invasive bladder cancer (NMIBC). This surgical treatment was novel and safety and efficacy of the treatment has not been established. We collected relative data in Shandong Provincial Hospital Affiliated to Shandong First Medical University from May 2018 to December 2020. Preoperative, intraoperative and postoperative clinical data were collected and analysed. The safety and efficacy of the novel surgical treatment were verified by the short-term and long-term clinical outcomes. Fifty patients with NMIBC were planed to be enrolled in the study.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Cancer
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedMar 22, 2022
Enrollment StartMay 1, 2018
Primary CompletionDec 30, 2020
Study CompletionMar 18, 2022
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 4.3 years ago